A comparative study of orphan drug prices in Europe

Journal of Market Access and Health Policy

Volumn 5, Issue 1, 2017, Pages

  Young, Katherine Eve ^a   Soussi, Imen ^a   Hemels, Michiel ^b   Toumi, Mondher ^c  

^a CREATIV CEUTICAL   (France)

^b Horizon Pharma BV   (Netherlands)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Europe; orphan drugs; pricing; Rare diseases; treatment cost

Indexed keywords

EID: 85064447478     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.1080/20016689.2017.1297886     Document Type: Article

References (42)

1. European Medicines Agency (EMA). Orphan drugs and rare diseases at a glance. [cited 13 Jul 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069805.pdf
2. NICE. Citizens council report ultra orphan drugs. [cited 14 Jul 2016]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885144/pdf/bcp0062-0264.pdf
3. Hughes W, Palma A, Schuurman A, et al. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orpanet J Rare Dis. 2012;7:1. Available from: http://www.ojrd.com/content/7/1/74
4. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
5. Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & EURODIS. Paris (France): EURODIS; 2010.
6. Heemstra HE. Variations in access and use of orphan drugs among EU member states. Eur J Hosp Pharm Pract. 2010;15(4):25–13.
7. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97:173–179.
8. Gammie T, Lu CY, Babar ZU-D, et al. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. Plos ONE. 2015;10(10):e0140002.
9. Toumi M, Rémuzat C, Vataire AL, et al. External reference pricing of medicinal products: simulation based considerations for cross country coordination. 2013. Available from: http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf
10. Aymé S, Rodwell C, editors. 2012 Report on the state of the art of rare disease activities in Europe of the European Union Committee of experts on rare diseases. Jul 2012. Available from: http://ec.europa.eu/health//sites/health/files/rare_diseases/docs/eucerd2012_report_state_of_art_rare_diseases_activities_5.pdf.
11. Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Dis Orphan Drugs: Int J Public Health. 2014;1(3):86–97.
12. Bouslouk M. G-BA benefit assessment of new orphan drugs in Germany: the first five years. Expert Opinion Orphan Drugs. 2016;4(5):453–455. DOI:10.1517/21678707.2016.1166950
13. Garau M, Mestre-Ferrandiz J. Access mechanisms for orphan drugs: A comparative study of selected European countries. OHE Breifing. 2009;52:1–32. Available from: https://www.ohe.org/publications/access-mechanisms-orphan-drugs-comparative-study-selected-european-countries.
14. Festøy H, Ognøy A WHO PPRI pharma profile Norway. Jun 2015. Available from: https://legemiddelverket.no/Documents/English/Price%20and%20reimbursement/PPRI_Pharma_Profile_Norway_20150626_final.pdf
15. NICE. Interim process and methods of the highly specialised technologies programme. 2013. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-highly-specialised-technologies-guidance/Highly-Specialised-Technologies-Interim-methods-and-process-statements.pdf
16. SMC. PACE (Patient & Clinician Engagement) overview document process changes for end of life and very rare conditions (orphan and ultra-orphan medicines). 2013. Available from: https://www.scottishmedicines.org.uk/files/PACE/PACE_Overview_Document_V2.pdf
17. Drummond M, Towse A. Orphan drug policies: a suitable case for treatment. Eur J Health Econ. 2014;15:335–340.
18. Schlander M, Holm S, Nord E et al. Towards social cost value analyis: the need for new approaches for evaluating drugs for ultra-rare disorders (Urds). Institute for Innovation and Valuation in Health Care. 2015. [cited Jul 2016]. Available from: http://www.innoval-hc.com/discussion-papers.html
19. Gutierrez L, Patris J, Hutchings A, et al. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10:53.
20. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis. 2011;6:62.
21. Côté A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15:1185–1191.
22. Simoens S, Cassiman D, Dooms M, et al. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437–1443.
23. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–29.
24. Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: influenceof orphan designation status on price. Appl Health Econ Health Policy. 2011;9(4):275–279.
25. Picavet, Picavet E, Morel T, et al. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62.
26. IHS PharmOnline International (POLI). [cited Jun 2016]. Available from: https://www.ihs.com/products/pharmaonline-international.html
27. Ameli. [cited Jul 2016]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
28. The British National Formulary (BNF). [cited Jul 2016]. Available from: https://www.medicinescomplete.com/mc/login.htm
29. Farmadati. [cited Jul 2016]. Available from: http://www.farmadati.it/
30. WHO. Child Growth Standards: weight for Age. [cited Jul 2016]. Available from: http://www.who.int/childgrowth/standards/weight_for_age/en/
31. Alcimed. Study on orphan drugs. Paris. 2005. Available from: http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
32. Macarthur D. Orphan drugs in Europe: pricing, reimbursement, funding & market access issues. Justpharmareports. USA: Arrowhead publishers; 2011.
33. Onakpoya I, Spencer EA, Thompson MJ, et al. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open. 2015;5:e007199.
34. Nicod E, Kanavos P. Scientific and social value judgments for orphan drugs in health technology assessment. Int J Technol Assess Health Care. 2016;32(4):1–15.
35. European Parliament Directorate-General for Internal Policies. Differences in costs of and access to pharmaceutical products in the EU. 2011. Available from: http://www.europarl.europa.eu/RegData/etudes/etudes/join/2011/451481/IPOL-ENVI_ET(2011)451481_EN.pdf.
36. European Commission. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Luxembourg: Publications Office of the European Union. Dec, 2015. Available from: http://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/pharmaproductpricing_frep_en.pdf.
37. Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16:1163–1169.
38. Paulden M, Stafinski T, Menon D, et al. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33:255–269.
39. Wagner M, Khoury H, Willet J, et al. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. Pharmacoeconomics. 2016;34:285–301.
40. Palaska C, Hutchings A. Value assessment and pricing frameworks for rare disease treatments: new approaches from the literature. ISPOR 18th Annual European Congress; Nov 2015; Milan, Italy. Available from: http://www.ispor.org/research_pdfs/51/pdffiles/PSY113.pdf
41. Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Orphanet J Rare Dis. 2013;8:18044.
42. US Forex Foreign Exchange Services. [cited Oct 2016]. Available from: http://www.usforex.com/forex-tools/historical-rate-tools/yearly-average-rates